312 related articles for article (PubMed ID: 37892174)
1. The Insulin-Degrading Enzyme from Structure to Allosteric Modulation: New Perspectives for Drug Design.
Tundo GR; Grasso G; Persico M; Tkachuk O; Bellia F; Bocedi A; Marini S; Parravano M; Graziani G; Fattorusso C; Sbardella D
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892174
[TBL] [Abstract][Full Text] [Related]
2. Toward Allosterically Increased Catalytic Activity of Insulin-Degrading Enzyme against Amyloid Peptides.
Kurochkin IV; Guarnera E; Wong JH; Eisenhaber F; Berezovsky IN
Biochemistry; 2017 Jan; 56(1):228-239. PubMed ID: 27982586
[TBL] [Abstract][Full Text] [Related]
3. Degradation of Alzheimer's Amyloid-β by a Catalytically Inactive Insulin-Degrading Enzyme.
Sahoo BR; Panda PK; Liang W; Tang WJ; Ahuja R; Ramamoorthy A
J Mol Biol; 2021 Jun; 433(13):166993. PubMed ID: 33865867
[TBL] [Abstract][Full Text] [Related]
4. Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease.
Kurochkin IV; Guarnera E; Berezovsky IN
Trends Pharmacol Sci; 2018 Jan; 39(1):49-58. PubMed ID: 29132916
[TBL] [Abstract][Full Text] [Related]
5. Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.
Tang WJ
Trends Endocrinol Metab; 2016 Jan; 27(1):24-34. PubMed ID: 26651592
[TBL] [Abstract][Full Text] [Related]
6. The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme: a biological perspective.
de Tullio MB; Morelli L; Castaño EM
Prion; 2008; 2(2):51-6. PubMed ID: 19098445
[TBL] [Abstract][Full Text] [Related]
7. Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
Çakir B; Dağliyan O; Dağyildiz E; Bariş İ; Kavakli IH; Kizilel S; Türkay M
PLoS One; 2012; 7(2):e31787. PubMed ID: 22355395
[TBL] [Abstract][Full Text] [Related]
8. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis.
Qiu WQ; Folstein MF
Neurobiol Aging; 2006 Feb; 27(2):190-8. PubMed ID: 16399206
[TBL] [Abstract][Full Text] [Related]
9. Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications.
Jha NK; Jha SK; Kumar D; Kejriwal N; Sharma R; Ambasta RK; Kumar P
J Alzheimers Dis; 2015; 48(4):891-917. PubMed ID: 26444774
[TBL] [Abstract][Full Text] [Related]
10. Insulysin: an allosteric enzyme as a target for Alzheimer's disease.
Song ES; Hersh LB
J Mol Neurosci; 2005; 25(3):201-6. PubMed ID: 15800373
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of Aβ by insulin degrading enzyme (IDE) in Alzheimer's disease.
Del Campo M; Stargardt A; Veerhuis R; Reits E; Teunissen CE
Neurosci Lett; 2015 Mar; 589():47-51. PubMed ID: 25597881
[TBL] [Abstract][Full Text] [Related]
12. Identification and functional characterization of a putative IDE, C28F5.4 (ceIDE-1), in Caenorhabditis elegans: Implications for Alzheimer's disease.
Haque R; Nazir A
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2454-2462. PubMed ID: 27443962
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Insulin Degrading Enzyme to Control Diabetes Mellitus and its Applications on some Other Chronic Disease: a Critical Review.
Azam MS; Wahiduzzaman M; Reyad-Ul-Ferdous M; Islam MN; Roy M
Pharm Res; 2022 Apr; 39(4):611-629. PubMed ID: 35378698
[TBL] [Abstract][Full Text] [Related]
14. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation.
Qiu WQ; Walsh DM; Ye Z; Vekrellis K; Zhang J; Podlisny MB; Rosner MR; Safavi A; Hersh LB; Selkoe DJ
J Biol Chem; 1998 Dec; 273(49):32730-8. PubMed ID: 9830016
[TBL] [Abstract][Full Text] [Related]
15. Conformational states and recognition of amyloidogenic peptides of human insulin-degrading enzyme.
McCord LA; Liang WG; Dowdell E; Kalas V; Hoey RJ; Koide A; Koide S; Tang WJ
Proc Natl Acad Sci U S A; 2013 Aug; 110(34):13827-32. PubMed ID: 23922390
[TBL] [Abstract][Full Text] [Related]
16. Reduced amyloid-β degradation in early Alzheimer's disease but not in the APPswePS1dE9 and 3xTg-AD mouse models.
Stargardt A; Gillis J; Kamphuis W; Wiemhoefer A; Kooijman L; Raspe M; Benckhuijsen W; Drijfhout JW; Hol EM; Reits E
Aging Cell; 2013 Jun; 12(3):499-507. PubMed ID: 23534431
[TBL] [Abstract][Full Text] [Related]
17. Insulin-degrading enzyme: structure-function relationship and its possible roles in health and disease.
Fernández-Gamba A; Leal MC; Morelli L; Castaño EM
Curr Pharm Des; 2009; 15(31):3644-55. PubMed ID: 19925417
[TBL] [Abstract][Full Text] [Related]
18. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.
Farris W; Mansourian S; Chang Y; Lindsley L; Eckman EA; Frosch MP; Eckman CB; Tanzi RE; Selkoe DJ; Guenette S
Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4162-7. PubMed ID: 12634421
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the Activity of the Insulin-Degrading Enzyme by Aβ Peptides.
Kemeh MM; Lazo ND
ACS Chem Neurosci; 2023 Aug; 14(16):2935-2943. PubMed ID: 37498802
[TBL] [Abstract][Full Text] [Related]
20. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention.
Zhao L; Teter B; Morihara T; Lim GP; Ambegaokar SS; Ubeda OJ; Frautschy SA; Cole GM
J Neurosci; 2004 Dec; 24(49):11120-6. PubMed ID: 15590928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
